Search
Abcellera Biologics Inc
ABCLAdd to Watchlist
7.600USD
-0.250-3.18%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.31BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.18%
5 Days
+34.99%
1 Month
+23.18%
6 Months
+122.22%
Year to Date
+122.22%
1 Year
+121.57%
Key Figures
7.690Open
7.850High
7.98MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.63%Turnover Ratio
7.850Prev. Close
7.265Low
39.63MTurnover
LossP/E Static
2.46P/B
0.00%Div Yield TTM
-10.86%ROA
6.51552wk High
0.61Volume Ratio
-162.86MNet Profit
303.95MShares
-0.4793EPS TTM
1.12Beta
-14.68%ROE
1.98052wk Low
7.45%Amplitude
100.00%Gross Margin
2.31BMarket Cap
5.89Reward/Risk
4.76%Risk Rate
TradingKey Stock Score of Abcellera Biologics Inc
Currency: USD Updated: 2026-06-30Key Insights
Abcellera Biologics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 106 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.43.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Abcellera Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Abcellera Biologics Inc Highlights
StrengthsRisks
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 97.58% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 75.13M.
Undervalued
The company’s latest PE is -16.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 131.69M shares, decreasing 12.73% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 1.46M shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
10.429
Target Price
+32.85%
Upside Space
Abcellera Biologics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Abcellera Biologics Inc Info
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Ticker SymbolABCL
CompanyAbcellera Biologics Inc
CEOHansen (Carl L.G)
Websitehttps://www.abcellera.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Abcellera Biologics Inc (ABCL)?
The current price of Abcellera Biologics Inc (ABCL) is 7.85.
What is the symbol of Abcellera Biologics Inc?
The ticker symbol of Abcellera Biologics Inc is ABCL.
What is the 52-week high of Abcellera Biologics Inc?
The 52-week high of Abcellera Biologics Inc is 6.51.
What is the 52-week low of Abcellera Biologics Inc?
The 52-week low of Abcellera Biologics Inc is 1.98.
What is the market capitalization of Abcellera Biologics Inc?
The market capitalization of Abcellera Biologics Inc is 2.40B.
Is Abcellera Biologics Inc (ABCL) currently rated as Buy, Hold, or Sell?
According to analysts, Abcellera Biologics Inc (ABCL) has an overall rating of Buy, with a price target of 10.43.
What is the Earnings Per Share (EPS TTM) of Abcellera Biologics Inc (ABCL)?
The Earnings Per Share (EPS TTM) of Abcellera Biologics Inc (ABCL) is -0.49.